Nashville, TNNCT07070219Now EnrollingIRB Ready

Acute Lymphocytic Leukemia Refractory Clinical Trial in Nashville, TN

Access cutting-edge acute lymphocytic leukemia refractory treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by BIOHENG THERAPEUTICS US LLC

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access acute lymphocytic leukemia refractory specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute lymphocytic leukemia refractory treatment provided free

Apply for This Nashville Location

Check if you qualify for this acute lymphocytic leukemia refractory clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Acute Lymphocytic Leukemia Refractory Study in Nashville

The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.

Sponsor: BIOHENG THERAPEUTICS US LLC

Who Can Participate

Inclusion Criteria

Male or female, ≥ 12 years of age.
Participants with body weight ≥ 40 kilogram.
Relapsed or refractory T-ALL/LBL is defined as one of the following:
Relapsed or refractory disease after two or more lines of systemic therapy;
The first relapse occurs within 12 months after first remission;
Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior to screening period.
The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologic evaluation or evidence of extramedullary disease at screening.
Have eligible HLA-matched related donor (MRD) or unrelated donor (URD), eligible haploidentical donor (HID) or syngeneic donors.
Adequate organ function
Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants \< 16) at screening. Key

Exclusion Criteria

Participants with concomitant genetic syndromes associated with bone marrow failure states or any other known bone marrow failure syndrome.
Active central nervous system (CNS) involvement
Participants with following cardiac conditions will be excluded:
History of heart failure New York Heart Association (NYHA) class III or IV;
History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.
Primary immune deficiency.
Presence of uncontrolled infections.
Known history of infection with the human immunodeficiency virus (HIV); hepatitis C virus and syphilis.
Active or latent hepatitis B virus infection
Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07070219) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphocytic Leukemia Refractory Treatment Options in Nashville, TN

If you're searching for acute lymphocytic leukemia refractory treatment options in Nashville, TN, this clinical trial (NCT07070219) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute lymphocytic leukemia refractory specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphocytic leukemia refractory clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Nashville, TN

See all leukemia clinical trials recruiting in Nashville — not just this study.

Browse Leukemia Trials in Nashville →

Browse More Trials by Condition

Leukemia TrialsHeart Attack TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN